A5073246821- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Hormonal and reproductive studies
- PARP inhibition in cancer therapy
- Medical Imaging Techniques and Applications
- Bone health and treatments
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Statistical Methods in Clinical Trials
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Boron Compounds in Chemistry
- Genital Health and Disease
- Advanced Radiotherapy Techniques
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Sexual Differentiation and Disorders
Mayo Clinic in Arizona
2023-2025
Mayo Clinic
2023-2025
Tulane University
2015-2024
Dana-Farber Cancer Institute
2005-2024
Memorial Sloan Kettering Cancer Center
2006-2024
Cornell University
2014-2024
Northwestern University
2002-2024
WinnMed
2023-2024
Huntsman Cancer Institute
2024
University of Utah
2017-2024
Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with particles. We assessed the efficacy and safety of radium-223 as compared placebo, in addition to best standard care, men castration-resistant prostate cancer metastases.
Multiple loss-of-function alterations in genes that are involved DNA repair, including homologous recombination associated with response to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition patients prostate and other cancers.
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic cancer. Lutetium-177 (177Lu)–PSMA-617 a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes PSA will often antedate bone scan. Furthermore, many but not all investigators have observed an association between decline levels of 50% or greater survival. Since the majority phase II clinical trials for androgen-independent cancer (AIPC) used as marker, we believed it was important to agree on definitions values...
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease progressed during previous treatment a next-generation hormonal agent. The results final analysis overall have not yet been reported. In an open-label, phase 3 trial, we randomly...
Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen with will further improve cancer control prolong overall survival unknown.
No AccessJournal of UrologyAdult Urology1 Nov 2009Prostate Specific Antigen Best Practice Statement: 2009 Updateis companion ofProstate Update Kirsten L. Greene, Peter C. Albertsen, Richard J. Babaian, H. Ballentine Carter, Gann, Misop Han, Deborah Ann Kuban, A. Oliver Sartor, Janet Stanford, Anthony Zietman, and Carroll GreeneKirsten Greene , AlbertsenPeter Albertsen BabaianRichard Babaian CarterH. Carter GannPeter Gann HanMisop Han KubanDeborah Kuban SartorA. Sartor StanfordJanet Stanford...
You have accessJournal of UrologyAUA Guideline1 Aug 2013Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guidelineis companion ofAdjuvant Versus Post-Prostatectomy Radiation Therapy: A Critical Review the Evidence Ian M. Thompson, Richard K. Valicenti, Peter Albertsen, Brian J. Davis, S. Larry Goldenberg, Carol Hahn, Eric Klein, Jeff Michalski, Mack Roach, Oliver Sartor, Stuart Wolf, Martha Faraday ThompsonIan Thompson , ValicentiRichard Valicenti AlbertsenPeter Albertsen...
Purpose This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen. Patients Methods Nine hundred fifty were randomly assigned (2:1) to receive (n = 635) 80 mg/m 2 on days 1 5 a 35-day cycle prednisone mg twice daily or placebo 315) daily. Primary end points...
Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated improved to ensure highest degree clinical relevance improve its utility for patient evaluation research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 no longer subclassified by extent involvement or laterality, 2) tumor grading includes both Gleason score (as in seventh criteria) grade group...
Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is significantly improved cabazitaxel versus mitoxantrone after prior docetaxel treatment. FIRSTANA ( ClinicalTrials.gov identifier: NCT01308567) assessed whether 20 mg/m2 (C20) or 25 (C25) superior to 75 (D75) in terms of OS chemotherapy-naïve mCRPC. Patients and Methods mCRPC Eastern Cooperative Oncology Group performance status 0 2 were randomly assigned 1:1:1 receive C20, C25, D75...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for ten most important areas of controversy in advanced prostate cancer (APC) management. successful registration several drugs castration-resistant recent studies chemo-hormonal therapy men with castration-naïve have led to considerable uncertainty as best treatment choices, sequence options appropriate patient selection. Management recommendations based on...
<h3>Importance</h3> Prostate cancer is the third leading cause of cancer-related death in men United States. Although serious, most these diagnoses are not terminal. Inherited risk for prostate associated with aggressive disease and poorer outcomes, indicating a critical need increased genetic screening to identify disease-causing variants that can pinpoint individuals at metastatic castration-resistant cancer. <h3>Objective</h3> To positive (pathogenic, likely pathogenic, risk) germline...
Abstract Emerging evidence suggests that mesenchymal stem cells (MSCs) are often recruited to tumor sites but their functional significance in growth and disease progression remains elusive. Herein we report prostate cancer (PC) cell microenvironment subverts PC patient adipose-derived (pASCs) undergo neoplastic transformation. Unlike normal ASCs, the pASCs primed with conditioned media (CM) formed prostate-like lesions vivo reproduced aggressive tumors secondary recipients. The pASC...